Patient characteristics
| Parameter . | Ofatumumab (n = 219) . | Rituximab (n = 219) . |
|---|---|---|
| Age,n (%), y | ||
| ≤65 | 148 (68) | 142 (65) |
| >65 | 71 (32) | 77 (35) |
| Age, y | ||
| Median (min, max) | 61.0 (27, 90) | 62 (26, 85) |
| Sex, n (%) | ||
| Female | 115 (53) | 109 (50) |
| Male | 104 (47) | 110 (50) |
| Ethnicity, n (%) | ||
| Hispanic or Latino | 15 (7) | 21 (10) |
| Not Hispanic or Latino | 204 (93) | 198 (90) |
| Race, n (%) | ||
| White | 122 (56) | 131 (60) |
| Asian | 89 (41) | 79 (36) |
| Other | 7 (3) | 6 (3) |
| Time since diagnosis, y | ||
| Median (min, max) | 4.7 (1, 24) | 5.3 (1, 20) |
| Time since disease progression, y | ||
| Median (min, max) | 0.1 (0, 13) | 0.2 (0, 13) |
| Number of prior therapies | ||
| Median (min, max) | 2 (1, 10) | 2 (1, 9) |
| Number of prior rituximab therapies | ||
| Median (min, max) | 1 (1, 6) | 1 (1, 8) |
| Rituximab-based therapy, n (%) | ||
| Any therapy | 219 (100) | 219 (100) |
| Monotherapy | 78 (36) | 84 (38) |
| Combination therapy | 199 (91) | 202 (92) |
| Collected FL international prognostic index-1 score, n (%) | ||
| 0-3 | 173 (79) | 165 (75) |
| 4 and 5 | 19 (9) | 15 (7) |
| Bulky lymphadenopathy at screening, n (%) | ||
| Yes | 13 (6) | 17 (8) |
| iNHL subtype, n (%) | ||
| FL | 214 (98) | 214 (98) |
| Non-FL | 5 (2) | 5 (2) |
| Prior anticancer therapy n (%) | ||
| Biologic therapy | 177 (81) | 169 (77) |
| Chemotherapy | 196 (89) | 199 (91) |
| Immunotherapy | 28 (13) | 43 (20) |
| Small molecule targeted therapy | 2 (<1) | 6 (3) |
| Other | 5 (2) | 4 (2) |
| Best response, n (%) | ||
| Complete response | 136 (62) | 140 (64) |
| Partial response | 74 (34) | 69 (32) |
| Stable disease | 4 (2) | 3 (1) |
| Progressive disease | 2 (<1) | 1 (<1) |
| Ann Arbor staging at screening (A + B), n (%) | ||
| I | 22 (10) | 18 (8.2) |
| II | 49 (22.4) | 41 (18.7) |
| III | 74 (33.8) | 80 (36.5) |
| IV A | 74 (33.8) | 80 (36.5) |
| Parameter . | Ofatumumab (n = 219) . | Rituximab (n = 219) . |
|---|---|---|
| Age,n (%), y | ||
| ≤65 | 148 (68) | 142 (65) |
| >65 | 71 (32) | 77 (35) |
| Age, y | ||
| Median (min, max) | 61.0 (27, 90) | 62 (26, 85) |
| Sex, n (%) | ||
| Female | 115 (53) | 109 (50) |
| Male | 104 (47) | 110 (50) |
| Ethnicity, n (%) | ||
| Hispanic or Latino | 15 (7) | 21 (10) |
| Not Hispanic or Latino | 204 (93) | 198 (90) |
| Race, n (%) | ||
| White | 122 (56) | 131 (60) |
| Asian | 89 (41) | 79 (36) |
| Other | 7 (3) | 6 (3) |
| Time since diagnosis, y | ||
| Median (min, max) | 4.7 (1, 24) | 5.3 (1, 20) |
| Time since disease progression, y | ||
| Median (min, max) | 0.1 (0, 13) | 0.2 (0, 13) |
| Number of prior therapies | ||
| Median (min, max) | 2 (1, 10) | 2 (1, 9) |
| Number of prior rituximab therapies | ||
| Median (min, max) | 1 (1, 6) | 1 (1, 8) |
| Rituximab-based therapy, n (%) | ||
| Any therapy | 219 (100) | 219 (100) |
| Monotherapy | 78 (36) | 84 (38) |
| Combination therapy | 199 (91) | 202 (92) |
| Collected FL international prognostic index-1 score, n (%) | ||
| 0-3 | 173 (79) | 165 (75) |
| 4 and 5 | 19 (9) | 15 (7) |
| Bulky lymphadenopathy at screening, n (%) | ||
| Yes | 13 (6) | 17 (8) |
| iNHL subtype, n (%) | ||
| FL | 214 (98) | 214 (98) |
| Non-FL | 5 (2) | 5 (2) |
| Prior anticancer therapy n (%) | ||
| Biologic therapy | 177 (81) | 169 (77) |
| Chemotherapy | 196 (89) | 199 (91) |
| Immunotherapy | 28 (13) | 43 (20) |
| Small molecule targeted therapy | 2 (<1) | 6 (3) |
| Other | 5 (2) | 4 (2) |
| Best response, n (%) | ||
| Complete response | 136 (62) | 140 (64) |
| Partial response | 74 (34) | 69 (32) |
| Stable disease | 4 (2) | 3 (1) |
| Progressive disease | 2 (<1) | 1 (<1) |
| Ann Arbor staging at screening (A + B), n (%) | ||
| I | 22 (10) | 18 (8.2) |
| II | 49 (22.4) | 41 (18.7) |
| III | 74 (33.8) | 80 (36.5) |
| IV A | 74 (33.8) | 80 (36.5) |
min, minimum; max, maximum.